Status:
COMPLETED
A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
Lead Sponsor:
AstraZeneca
Conditions:
Obesity or Overweight
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 we...
Detailed Description
The study will comprise of: A screening period of maximum 28 days A treatment period of 36 weeks A follow up period after last dose of study drug This study will consist of 4 cohorts. Approximatel...
Eligibility Criteria
Inclusion
- Adults ≥ 18 years of age
- BMI of (a) ≥ 30 kg/m2, or (b) ≥ 27kg/m2 and have a current diagnosis of at least 1 weight-related comorbidities (treated or untreated)
- A stable body weight for 3 months prior to Screening (±5% body weight change)
Exclusion
- Have obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome
- Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening
- Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
- History of type 1 diabetes mellitus or T2DM
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 3 2025
Estimated Enrollment :
262 Patients enrolled
Trial Details
Trial ID
NCT06595238
Start Date
October 1 2024
End Date
December 3 2025
Last Update
December 17 2025
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Mobile, Alabama, United States, 36608
2
Research Site
Phoenix, Arizona, United States, 85044
3
Research Site
Long Beach, California, United States, 90815
4
Research Site
Hialeah, Florida, United States, 33012